X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs CIPLA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE CIPLA CADILA HEALTHCARE/
CIPLA
 
P/E (TTM) x 34.3 43.6 78.8% View Chart
P/BV x 8.8 3.6 246.2% View Chart
Dividend Yield % 0.7 0.4 193.6%  

Financials

 CADILA HEALTHCARE   CIPLA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-16
CIPLA
Mar-17
CADILA HEALTHCARE/
CIPLA
5-Yr Chart
Click to enlarge
High Rs454622 73.1%   
Low Rs305458 66.4%   
Sales per share (Unadj.) Rs96.1181.9 52.8%  
Earnings per share (Unadj.) Rs14.912.9 115.6%  
Cash flow per share (Unadj.) Rs17.829.3 60.8%  
Dividends per share (Unadj.) Rs3.202.00 160.0%  
Dividend yield (eoy) %0.80.4 227.7%  
Book value per share (Unadj.) Rs52.3155.7 33.6%  
Shares outstanding (eoy) m1,023.74804.51 127.3%   
Bonus/Rights/Conversions FV5:1ESOP-  
Price / Sales ratio x3.93.0 133.0%   
Avg P/E ratio x25.542.0 60.8%  
P/CF ratio (eoy) x21.318.4 115.5%  
Price / Book Value ratio x7.33.5 209.2%  
Dividend payout %21.515.5 138.5%   
Avg Mkt Cap Rs m388,458434,516 89.4%   
No. of employees `00015.423.0 67.0%   
Total wages/salary Rs m13,31726,338 50.6%   
Avg. sales/employee Rs Th6,371.16,349.1 100.3%   
Avg. wages/employee Rs Th862.41,143.0 75.5%   
Avg. net profit/employee Rs Th986.1449.3 219.4%   
INCOME DATA
Net Sales Rs m98,376146,302 67.2%  
Other income Rs m9412,287 41.1%   
Total revenues Rs m99,317148,589 66.8%   
Gross profit Rs m23,82924,758 96.2%  
Depreciation Rs m3,02213,229 22.8%   
Interest Rs m4861,594 30.5%   
Profit before tax Rs m21,26212,222 174.0%   
Minority Interest Rs m-3000-   
Prior Period Items Rs m5-70 -7.2%   
Extraordinary Inc (Exp) Rs m-250-   
Tax Rs m5,7161,798 318.0%   
Profit after tax Rs m15,22610,354 147.1%  
Gross profit margin %24.216.9 143.1%  
Effective tax rate %26.914.7 182.8%   
Net profit margin %15.57.1 218.7%  
BALANCE SHEET DATA
Current assets Rs m44,37687,370 50.8%   
Current liabilities Rs m34,07133,081 103.0%   
Net working cap to sales %10.537.1 28.2%  
Current ratio x1.32.6 49.3%  
Inventory Days Days5487 61.9%  
Debtors Days Days6262 100.1%  
Net fixed assets Rs m47,896111,567 42.9%   
Share capital Rs m1,0241,609 63.6%   
"Free" reserves Rs m48,746123,645 39.4%   
Net worth Rs m53,519125,254 42.7%   
Long term debt Rs m8,96436,454 24.6%   
Total assets Rs m100,163209,532 47.8%  
Interest coverage x44.78.7 516.2%   
Debt to equity ratio x0.20.3 57.6%  
Sales to assets ratio x1.00.7 140.7%   
Return on assets %15.75.7 275.1%  
Return on equity %28.48.3 344.2%  
Return on capital %34.38.5 403.4%  
Exports to sales %45.334.2 132.3%   
Imports to sales %5.98.3 71.1%   
Exports (fob) Rs m44,53750,050 89.0%   
Imports (cif) Rs m5,83812,203 47.8%   
Fx inflow Rs m44,88151,066 87.9%   
Fx outflow Rs m9,06917,678 51.3%   
Net fx Rs m35,81233,388 107.3%   
CASH FLOW
From Operations Rs m19,93823,824 83.7%  
From Investments Rs m-9,039-13,127 68.9%  
From Financial Activity Rs m-9,527-13,239 72.0%  
Net Cashflow Rs m1,372-2,478 -55.4%  

Share Holding

Indian Promoters % 74.8 16.0 467.5%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 8.3 12.2 68.0%  
FIIs % 5.9 23.7 24.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 11.0 26.2 42.0%  
Shareholders   44,069 161,166 27.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT LTD.  SUVEN LIFE  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Aug 23, 2017 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS